CLDX Celldex Therapeutics Inc

Price (delayed)

$38.5

Market cap

$1.82B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.65

Enterprise value

$1.8B

Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which ...

Highlights
The company's gross profit rose by 34% QoQ
Celldex Therapeutics's revenue has increased by 34% from the previous quarter
CLDX's quick ratio has dropped by 57% year-on-year and by 48% since the previous quarter
Celldex Therapeutics's equity has decreased by 29% YoY and by 11% from the previous quarter

Key stats

What are the main financial stats of CLDX
Market
Shares outstanding
47.26M
Market cap
$1.82B
Enterprise value
$1.8B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
7.37
Price to sales (P/S)
416.85
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
412.69
Earnings
Revenue
$4.37M
EBIT
-$124.61M
EBITDA
-$121.69M
Free cash flow
-$97.91M
Per share
EPS
-$2.65
Free cash flow per share
-$2.07
Book value per share
$5.22
Revenue per share
$0.09
TBVPS
$5.35
Balance sheet
Total assets
$280.26M
Total liabilities
$33.54M
Debt
$2.85M
Equity
$246.72M
Working capital
$218.1M
Liquidity
Debt to equity
0.01
Current ratio
8.84
Quick ratio
8.46
Net debt/EBITDA
0.15
Margins
EBITDA margin
-2,787.8%
Gross margin
100%
Net margin
-2,854.8%
Operating margin
-3,088.2%
Efficiency
Return on assets
-39.7%
Return on equity
-43.2%
Return on invested capital
-52.4%
Return on capital employed
-49.4%
Return on sales
-2,854.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CLDX stock price

How has the Celldex Therapeutics stock price performed over time
Intraday
0.65%
1 week
9.16%
1 month
-3.73%
1 year
-10.51%
YTD
-2.92%
QTD
-2.92%

Financial performance

How have Celldex Therapeutics's revenue and profit performed over time
Revenue
$4.37M
Gross profit
$4.37M
Operating income
-$134.8M
Net income
-$124.61M
Gross margin
100%
Net margin
-2,854.8%
The net margin has soared by 71% YoY and by 18% QoQ
CLDX's operating margin has surged by 71% year-on-year and by 17% since the previous quarter
The company's gross profit rose by 34% QoQ
Celldex Therapeutics's revenue has increased by 34% from the previous quarter

Growth

What is Celldex Therapeutics's growth rate over time

Valuation

What is Celldex Therapeutics stock price valuation
P/E
N/A
P/B
7.37
P/S
416.85
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
412.69
CLDX's EPS is down by 17% YoY and by 10% from the previous quarter
The P/B is 117% higher than the 5-year quarterly average of 3.4 and 27% higher than the last 4 quarters average of 5.8
Celldex Therapeutics's equity has decreased by 29% YoY and by 11% from the previous quarter
Celldex Therapeutics's revenue has increased by 34% from the previous quarter
CLDX's price to sales (P/S) is 25% lower than its last 4 quarters average of 554.1 but 20% higher than its 5-year quarterly average of 348.5

Efficiency

How efficient is Celldex Therapeutics business performance
CLDX's ROS has soared by 71% YoY and by 18% from the previous quarter
Celldex Therapeutics's ROIC has plunged by 68% YoY and by 22% from the previous quarter
The ROE has plunged by 56% YoY and by 20% from the previous quarter
The ROA has shrunk by 54% YoY and by 18% QoQ

Dividends

What is CLDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CLDX.

Financial health

How did Celldex Therapeutics financials performed over time
The current ratio has plunged by 57% YoY and by 48% from the previous quarter
CLDX's quick ratio has dropped by 57% year-on-year and by 48% since the previous quarter
The debt is 99% lower than the equity
Celldex Therapeutics's equity has decreased by 29% YoY and by 11% from the previous quarter
The debt has decreased by 22% YoY and by 13% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.